Guardant Health, Inc. (GH) Insider Trading Activity

NASDAQ$97.89-4.75 (-4.63%)
Market Cap
$12.74B
Sector
Healthcare
Industry
Medical—Diagnostics & Research
Rank in Sector
556 of 826
Rank in Industry
22 of 43

GH Insider Trading Activity

GH Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$65,829,141
45
100

Related Transactions

POTTER MYRTLE Sdirector
0
$0
6
$137,773
$-137,773
Joyce Meghan V.director
0
$0
4
$172,594
$-172,594
Tariq Musadirector
0
$0
12
$225,687
$-225,687
Hidalgo Medina Manueldirector
0
$0
4
$486,446
$-486,446
Kalia KumudChief Information Officer
0
$0
4
$669,336
$-669,336
Saia John G.Chief Legal Officer
0
$0
1
$865,865
$-865,865
Chudova DaryaChief Technology Officer
0
$0
1
$2.42M
$-2.42M
Freeman ChrisChief Commercial Officer
0
$0
1
$3.24M
$-3.24M
CLARK IAN Tdirector
0
$0
2
$3.39M
$-3.39M
Monroe Terilyn J.Chief People Officer
0
$0
1
$5.85M
$-5.85M
Bell Michael BrianChief Financial Officer
0
$0
1
$8.29M
$-8.29M
Eltoukhy HelmyCo-Chief Executive Officer
0
$0
1
$17.84M
$-17.84M
Talasaz AmirAliCo-Chief Executive Officer
0
$0
7
$22.25M
$-22.25M

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Insider Activity of Guardant Health, Inc.

Over the last 12 months, insiders at Guardant Health, Inc. have bought $0 and sold $65.83M worth of Guardant Health, Inc. stock.

On average, over the past 5 years, insiders at Guardant Health, Inc. have bought $8.18M and sold $100.64M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,187 shares for transaction amount of $38,963 was made by Kalia Kumud (Chief Information Officer) on 2024‑03‑18.

List of Insider Buy and Sell Transactions, Guardant Health, Inc.

2025-12-08SaleTalasaz AmirAliCo-Chief Executive Officer
50,000
0.0406%
$105.05
$5.25M
-2.54%
2025-12-08SaleKalia KumudChief Information Officer
2,000
0.0016%
$104.60
$209,204
-2.54%
2025-12-08SaleChudova DaryaChief Technology Officer
22,935
0.0187%
$105.43
$2.42M
-2.54%
2025-12-08SaleHidalgo Medina Manueldirector
1,250
0.001%
$105.00
$131,250
-2.54%
2025-12-05SaleBell Michael BrianChief Financial Officer
80,362
0.0654%
$103.14
$8.29M
-3.77%
2025-12-05SaleFreeman ChrisChief Commercial Officer
31,452
0.0256%
$103.07
$3.24M
-3.77%
2025-12-05SaleCLARK IAN Tdirector
28,611
0.0242%
$107.19
$3.07M
-3.77%
2025-12-01SaleMonroe Terilyn J.Chief People Officer
55,167
0.0448%
$105.97
$5.85M
-1.48%
2025-11-19SaleTariq Musadirector
116
<0.0001%
$96.25
$11,165
+5.85%
2025-11-07SaleSaia John G.Chief Legal Officer
8,996
0.0075%
$96.25
$865,865
+6.86%
2025-11-07SaleHidalgo Medina Manueldirector
1,000
0.0008%
$95.17
$95,165
+6.86%
2025-11-07SaleHidalgo Medina Manueldirector
1,500
0.0012%
$95.19
$142,780
+6.86%
2025-10-17SalePOTTER MYRTLE Sdirector
26
<0.0001%
$66.95
$1,741
+49.76%
2025-10-17SaleTariq Musadirector
116
<0.0001%
$66.95
$7,766
+49.76%
2025-09-17SalePOTTER MYRTLE Sdirector
26
<0.0001%
$55.63
$1,446
+62.12%
2025-09-17SaleTariq Musadirector
116
<0.0001%
$55.63
$6,453
+62.12%
2025-09-12SaleHidalgo Medina Manueldirector
2,165
0.0017%
$54.16
$117,251
+31.64%
2025-09-09SaleEltoukhy HelmyCo-Chief Executive Officer
300,000
0.2406%
$59.45
$17.84M
+20.29%
2025-09-02SaleJoyce Meghan V.director
100
<0.0001%
$65.84
$6,584
+4.62%
2025-08-21SaleKalia KumudChief Information Officer
2,000
0.0016%
$61.76
$123,510
+10.13%
Total: 275
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Eltoukhy HelmyCo-Chief Executive Officer
2123499
1.7104%
$217.96M438
<0.0001%
Talasaz AmirAliCo-Chief Executive Officer
168223
0.1355%
$17.27M455
<0.0001%
Saia John G.Chief Legal Officer
43172
0.0348%
$4.43M01
Bell Michael BrianChief Financial Officer
28052
0.0226%
$2.88M01
Freeman ChrisChief Commercial Officer
25987
0.0209%
$2.67M01
Kalia KumudChief Information Officer
22365
0.018%
$2.3M210
+22.77%
Monroe Terilyn J.Chief People Officer
20920
0.0169%
$2.15M01
POTTER MYRTLE Sdirector
18324
0.0148%
$1.88M06
Chudova DaryaChief Technology Officer
12463
0.01%
$1.28M01
Joyce Meghan V.director
11183
0.009%
$1.15M011
CLARK IAN Tdirector
9851
0.0079%
$1.01M042
Tariq Musadirector
7859
0.0063%
$806,647.76013
Hidalgo Medina Manueldirector
797
0.0006%
$81,804.0804
SOFTBANK VISION FUND (AIV M1) L.P.10 percent owner
27850460
22.4329%
$2.86B10
+5.91%
SVF Bluebird (Cayman) Ltd10 percent owner
7037960
5.6689%
$722.38M04
Wiley Michael JChief Legal Officer
111171
0.0895%
$11.41M013
Lanman Richard B.Chief Medical Officer
82015
0.0661%
$8.42M07
Merrill AmeliaSVP, People
20208
0.0163%
$2.07M01
Kaul Samirdirector
14943
0.012%
$1.53M07
BERTOCCI DEREK AChief Financial Officer
6373
0.0051%
$654,124.72011
MERESMAN STANLEY J
4059
0.0033%
$416,615.76036
Nishar Dipchanddirector
2321
0.0019%
$238,227.4401
*Gray background shows insiders who have made transactions during last year

GH Institutional Investors: Active Positions

Increased Positions204+50.75%19M+14.97%
Decreased Positions174-43.28%19M-15.5%
New Positions71New4MNew
Sold Out Positions38Sold Out3MSold Out
Total Postitions432+7.46%124M-0.53%

GH Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Vanguard Group Inc$1.22M9.23%11.91M-259,191-2.13%2025-09-30
Blackrock, Inc.$1.17M8.86%11.43M+449,845+4.1%2025-09-30
Baillie Gifford & Co$523,384.003.98%5.13M+317,906+6.61%2025-09-30
Invesco Ltd.$503,158.003.82%4.93M+1M+38.53%2025-09-30
Capital International Investors$478,631.003.64%4.69M-287,217-5.77%2025-09-30
Price T Rowe Associates Inc /Md/$430,902.003.27%4.22M+2M+139.11%2025-09-30
Deep Track Capital, Lp$424,008.003.22%4.15M-95,914-2.26%2025-09-30
Eventide Asset Management, Llc$339,009.002.58%3.32M-137,625-3.98%2025-09-30
Wellington Management Group Llp$331,634.002.52%3.25M+1M+68.96%2025-09-30
Geode Capital Management, Llc$299,744.002.28%2.94M+15,942+0.55%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.